Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.51 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848723 | 0.95 | PTGS2 (0.47) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL5848706 | 0.91 | PTGS2 (0.45) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL5850216 | 0.87 | PTGS2 (0.52) | PTGS2PTGS1L3MBTL1 | |
| SCHEMBL5847976 | 0.87 | PTGS2 (0.52) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL5850196 | 0.82 | PTGS2 (0.47) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL5848426 | 0.81 | PTGS2 (0.61) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL5849857 | 0.81 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL5848442 | 0.79 | PTGS2 (0.44) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL5850185 | 0.79 | PTGS2 (0.45) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL5847947 | 0.77 | PTGS2 (0.64) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112605-B2 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | Research Institute of Materia Medica Chinese Acadamy of Medical Sciences (CN) | 2006-09-26 | — | — | US | claimed |
| US-7112605-B2 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | Research Institute of Materia Medica Chinese Acadamy of Medical Sciences (CN) | 2006-09-26 | — | — | US | disclosed |
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | RESEARCH INSTITUTE OF MATERIAL MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES; | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | PTGS1, PTGS2, PTGER1 | PTGS2 2/4885PTGS1 1/4885CA12 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.